Table 2.

Demographics and baseline characteristics in ublituximab-treated participants with or without NEDA-3 at Weeks 0–96.^a

Characteristic	Evaluated ublituximab-treated population
Mean ±standard deviation or %	With NEDA-3 (n = 232)	Without NEDA-3 (n = 288)
Age, years	36.5 ± 8.9	34.4 ± 8.5
Sex, female, %	62.1	64.2
Region, %
US & Western Europe	6.0	10.8
Eastern Europe	94.0	89.2
Duration of MS since first symptoms, years	7.8 ± 6.7	7.1 ± 6.1
Time since diagnosis, years	5.1 ± 5.5	4.7 ± 5.1
Number of relapses in last 12 months*	1.2 ± 0.5	1.4 ± 0.7
Number of relapses in last 24 months†	1.7 ± 0.8	1.9 ± 1.1
Time since most recent relapse, months	7.0 ± 4.9	7.3 ± 10.7
EDSS score at screening	2.8 ± 1.2	2.9 ± 1.3
T2 lesion volume, mL‡	12.8 ± 14.3	17.2 ± 14.9
Number of T2 lesions§	55.3 ± 35.5	72.4 ± 41.5
Participants free of Gd+ T1 lesions§, %	70.3	36.8

^*p = 0.0018, ^†p = 0.0022, ^‡p = 0.0007, and ^§p <0.0001.

^aParticipants included in NEDA-3 analyses.

EDSS, Expanded Disability Status Scale; Gd+, gadolinium-enhancing; MS, multiple sclerosis; NEDA-3, 3-parameter no evidence of disease activity.